Wednesday, May 29, 2024
Evotec SE has recently announced the extension of its collaboration with CHDI Foundation, Inc. CHDI, a non-profit organization dedicated to advancing therapies for Huntington’s disease, aims to significantly enhance the quality of life for those affected by the condition. The renewed collaboration seeks to deepen our understanding of the disease, facilitating the development of novel treatments.
The collaboration leverages Evotec’s comprehensive neuroscience platform and extensive expertise in central nervous system (CNS) drug discovery and development. Spanning various domains including biology, chemistry, target validation, stem-cell research, high-content screening, computational chemistry, pharmacology, protein production, and biomarker discovery, this partnership operates across multiple locations. Originating in 2006, this collaboration stands as one of Evotec's most substantial strategic alliances in drug discovery.
Dr. Craig Johnstone, Chief Operating Officer of Evotec, expressed his satisfaction: “We are thrilled that CHDI acknowledges the value of our longstanding and deeply collaborative relationship. Our continuous efforts alongside CHDI in combating Huntington’s disease reflect our unwavering commitment to developing new therapies for those impacted by this devastating illness.”
Dr. Robert Pacifici, Chief Scientific Officer at CHDI, echoed this sentiment: “Throughout the past years, our partnership with Evotec has been instrumental in driving forward CHDI's preclinical research initiatives, serving as invaluable scientific allies in our quest to develop treatments for individuals affected by Huntington’s disease. We eagerly anticipate the continuation of our productive research collaboration.”
Source: evotec.com
